Other Information
−Removed: During the three months ended March 31, 2025, the following officer adopted Rule 10b5-1 trading arrangements (as such terms are defined pursuant to Item 408 of Regulation S-K) as noted in the table below.
+Added: During the three months ended June 30, 2025, the following officer adopted Rule 10b5-1 trading arrangements (as such terms are defined pursuant to Item 408 of Regulation S-K) as noted in the table below.
Trading Arrangement
3 unchanged sentences
Expiration Date
−Removed: 376,569 (1) The earlier of 12/12/2025 or the date all shares are sold
−Removed: President and Chief Executive Officer
−Removed: 251,923 (2) The earlier of 7/31/2026 or the date all shares are sold
−Removed: President and Chief Executive Officer
+Added: Bernadette Connaughton
+Added: 17,330 8/31/2026
+Added: Nicole LaBrosse
+Added: Senior Vice President and Chief Financial Officer
* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** Non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K under the Exchange Act.
−Removed: (1) Represents common shares to be sold following exercise of stock options with a ten-year term expiring in February 2026.
−Removed: (2) Represents common shares to be sold following exercise of stock options with a ten-year term expiring in February 2027.
−Removed: (3) The Rule 10b5-1 trading arrangements are sequential and do not overlap.
+Added: *** The total number of shares to be sold under this plan is 22,227 plus an undetermined number of shares to be sold resulting from the vesting of 17,110 restricted stock units less the amount of shares that will be withheld to satisfy the payment of tax withholding obligations due upon vesting.
3.1 Amended and Restated Certificate of Incorporation of Halozyme Therapeutics, Inc.
9 unchanged sentences
and The Bank of New York Mellon Trust Company, N.A., as trustee (included within Exhibit 4.3) ( filed as Exhibit 4.2 to the Company’s Form 8-K filed August 18, 2022 and incorporated herein by reference )
−Removed: Form of 2025 Deal / N omination Performance Stock Units Agreement (202 1 Stock Plan) (filed herewith)
−Removed: F orm of 2025 Relative TSR Performance Stock Units Agreement (2021 Stock Plan) (filed herewith)
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended (filed herewith)
9 unchanged sentences
104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) (filed herewith)
−Removed: # Indicates management contract or compensatory plan or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Halozyme Therapeutics, Inc.
−Removed: May 6, 2025 By:
+Added: August 5, 2025 By:
Ch.B., M.R.C.P.
2 unchanged sentences
(Principal Executive Officer)
−Removed: May 6, 2025 By:
+Added: August 5, 2025 By:
/s/ Nicole LaBrosse
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.